In This Article:
The U.S. healthcare sector experienced a turbulent trading session on April 17, 2025, as UnitedHealth’s UNH earnings disappointment sent ripples through insurer stocks. However, strong gains in drugmakers, particularly Eli Lilly LLY, helped make up for broader sector losses.
Insurers Take a Hit from UnitedHealth Fallout
UnitedHealth’s sharp 22.4% drop following weak earnings and soft guidance echoed across the insurer landscape, dragging down key players like CVS Health, Humana, and Elevance Health. The results spotlighted how exposed health insurers are to company-specific missteps and shifting policy risks.
Eli Lilly Offers a Safety Net
Despite the pressure on managed care, Eli Lilly’s 14.4% surge on April 17 served as a reminder of the power of innovation in driving sector performance. Eli Lilly announced that its experimental weight-loss pill, orforglipron, performed on par with the widely used injectable drug Ozempic in reducing both weight and blood sugar levels in patients with type 2 diabetes. Its success helped cushion sector-wide declines.
Stable Giants and Medical Tech in Focus
Johnson & Johnson JNJ maintained its stable trajectory, supported by solid earnings. JNJ shares gained 2.3% on the day. Meanwhile, medical device and equipment makers such as are increasingly hogging investor attention, benefiting from long-term demand trends tied to an aging global population.
Impact on the ETF World
Health Care Select Sector SPDR Fund (XLV): Insurers Drag, But Pharma Lifts the Mood
Health Care Select Sector SPDR Fund XLV houses Eli Lilly (12.29%), UnitedHealth (9%), and Johnson & Johnson (7.47%) among its top holdings. Overall, the fund lost 0.6% on the day.
iShares U.S. Pharmaceuticals ETF (IHE): Pharma-Powered Rally
iShares U.S. Pharmaceuticals ETF IHE saw a strong influx of investor interest as capital rotated into large-cap pharmaceutical stocks, spurred by Eli Lilly’s success.The rally came even as Novo Nordisk—a key competitor in the GLP-1 space—tumbled nearly 8%. IHE ETF jumped 4.6% on that day.
SPDR S&P Pharmaceuticals ETF (XPH): Another Pharma Gainer
SPDR S&P Pharmaceuticals ETF XPH gained on the back of widespread strength in the pharmaceutical sector. Investor enthusiasm, driven by innovation-led sentiment from Eli Lilly’s news, supported a broad rally in drug stocks. The XPH ETF rose 2.2% on April 17.
iShares U.S. Healthcare Providers ETF (IHF) : Hurt by Health Insurers’ Losses
iShares U.S. Healthcare Providers ETF IHF is heavy on UNH, Elevance Health ELV (down 2.4%), Humana HUM (down 7.4%), CVS Health Corporation CVS (down 1.84%). Due to the hit from these stocks, the fund dived over 6% on April 17.